Related Experiment Videos
Head and neck squamous cell carcinoma: optimizing the therapeutic index
David I Rosenthal1, Angel I Blanco
1Department of Radiation Oncology, 097, The University of Texas, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030-4009, USA. dirosenthal@mdanderson.org
Expert Review of Anticancer Therapy
|July 9, 2005
Summary
Advancements in head and neck cancer treatment, including altered radiation fractionation, chemotherapy, intensity-modulated radiation therapy, and targeted biologic therapy, improve outcomes but increase toxicity. Further research aims to optimize these strategies for better therapeutic ratios.
Area of Science:
- Oncology
- Radiation Oncology
- Head and Neck Cancer Research
Background:
- Head and neck squamous cell cancers (HNSCC) require effective curative treatments.
- Recent decades have seen significant progress in HNSCC therapeutic strategies.
- Balancing treatment efficacy with toxicity is a critical challenge in HNSCC management.
Purpose of the Study:
- To review recent advancements in HNSCC treatment.
- To discuss the benefits and challenges of combined modality treatments.
- To explore novel strategies for improving the therapeutic ratio in HNSCC.
Main Methods:
- Review of clinical investigations and therapeutic strategies over the last 30 years.
- Analysis of altered fractionation regimens, chemotherapy integration, intensity-modulated radiation therapy (IMRT), and targeted biologic therapy.
- Discussion of toxicity profiles (acute and late) associated with current treatments.
Main Results:
- Biologically sound altered fractionation and concurrent chemoradiation improve locoregional control and survival in HNSCC.
- Combined modality treatments can increase acute and late toxicities, such as mucositis, fibrosis, and dysphagia.
- Intensity-modulated radiation therapy (IMRT) allows for dose escalation to tumors while sparing normal tissues.
- Targeted biologic therapies offer potential for increased tumor cell kill with reduced normal tissue toxicity.
Conclusions:
- Combined modality treatments have redefined HNSCC care but require careful patient selection due to toxicity concerns.
- IMRT presents new fractionation questions and opportunities for optimizing radiation delivery.
- Future directions involve combining radiation therapy with targeted biologic agents to enhance efficacy and minimize toxicity in HNSCC treatment.